Canadian Guideline on HIV Pre-Exposure Prophylaxis and Nonoccupational Postexposure Prophylaxis
- Pre-exposure prophylaxis (PrEP) involving daily tenofovir disoproxil fumarate/emtricitabine 300/200 mg, taken orally, is a highly effective strategy for reducing the risk of HIV acquisition in adults who are at high, ongoing risk of infection.
- In gay, bisexual and other men who have sex with men with frequent exposures, an on-demand regimen may also be considered.
- Nonoccupational postexposure prophylaxis (nPEP) involving 28 days of antiretroviral medications is an effective strategy for reducing the risk of HIV acquisition from a recent (within 72 h) incident of moderate or high-risk exposure to HIV.
- PrEP and nPEP should be part of a combination prevention strategy that includes behavioural interventions, such as condoms and counselling on risk reduction.
- Letter of corrections and clarifications
- Appendix 1: Detailed Guideline
- Appendix 2: Clinical questions addressed by guideline
- Appendix 3: Study selection diagrams
- Appendix 4: Summary of findings tables
- Provincial/Territorial Coverage of ARV drugs for HIV prevention across Canada: Pre-exposure prophylaxis (PrEP) – Immunodeficiency Clinic, Toronto General Hospital